© 2021 Eye Center at St. Franziskus Hospital Münster
With deepeye, embark on a journey towards significantly enhanced treatment outcomes. Experience a seamless workflow, enriched with precise analysis of 3D retinal scans (OCTs), enabling more informed decisions in retinal therapy, particularly through intravitreal injections (IVI) utilizing anti-VEGF inhibitors. Your path towards optimized patient care begins here.
deepeye isn't just a tool, it's a commitment towards improving the lives of individuals afflicted with retinal diseases. With our AI-driven prognostics, prepare your patients for a better tomorrow, armed with a proactive treatment plan, reducing the treatment burden and fostering a future with clearer vision.
More than just data, deepeye delivers actionable insights, aiding in robust treatment planning that overcome the limitations of conventional treatment regimen like T&E, PRN, IVAN, and CATT. Our pursuit of algorithmic refinement aims to redefine the treatment narrative for retinal diseases towards a (patient) need-based "predict & treat" (P&T).
Why do we think it is possible to improve upon the current state-of-the-art?
Real-world studies using human expert 2nd opinions show that anti-VEGF therapy outcomes can be improved:
Therapy persistence from 38% to 78% = 2x more patients remaining in therapy after 24 months
Real-world vision outcomes from 36% to 100% = 3x higher visual acuity compared to average outcomes after 24 months in therapy
B. Sobolewska et al.
We value your feedback and understand that you may have questions or concerns regarding our medical device software products (not yet available for clinical use). Our Regulatory Affairs team is here to assist you. Whether you have a product complaint, a suggestion, or just need more information, we are happy to help. Your input is important to us and helps us continually improve our products and services.